Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
Author: Larson, R.
Hochhaus, A.
Hughes, T.
Clark, R.
Etienne, G.
Kim, D.
Flinn, I.
Kurokawa, M.
Moiraghi, B.
Yu, R.
Blakesley, R.
Gallagher, N.
Saglio, G.
Kantarjian, H.
Citation: Leukemia, 2012; 26(10):2197-2203
Publisher: Nature Publishing Group
Issue Date: 2012
ISSN: 0887-6924
Statement of
RA Larson, A Hochhaus, TP Hughes, RE Clark, G Etienne, D-W Kim, IW Flinn, M Kurokawa, B Moiraghi, R Yu, RE Blakesley, NJ Gallagher, G Saglio and HM Kantarjian
Abstract: Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients compares nilotinib and imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). With a minimum follow-up of 3 years, major molecular response, molecular response of BCR-ABLless than or equal to0.01% expressed on the international scale (BCR-ABLIS; MR4) and BCR-ABLISless than or equal to0.0032% (MR4.5) rates were significantly higher with nilotinib compared with imatinib, and differences in the depth of molecular response between nilotinib and imatinib have increased over time. No new progressions occurred on treatment since the 2-year analysis. Nilotinib was associated with a significantly lower probability of progression to accelerated phase/blast crisis vs imatinib (two (0.7%) progressions on nilotinib 300 mg twice daily, three (1.1%) on nilotinib 400 mg twice daily and 12 (4.2%) on imatinib). When considering progressions occurring after study treatment discontinuation, the advantage of nilotinib over imatinib in preventing progression remained significant (nine (3.2%) progressions on nilotinib 300 mg twice daily, six (2.1%) on nilotinib 400 mg twice daily and 19 (6.7%) on imatinib). Both nilotinib and imatinib were well tolerated, with minimal changes in safety over time. Nilotinib continues to demonstrate superior efficacy in all key response and outcome parameters compared with imatinib for the treatment of patients with newly diagnosed CML-CP.
Keywords: chronic myeloid leukemia; ENESTnd; nilotinib; imatinib; progression; newly diagnosed
Description: Extent: 7p.
Rights: © 2012 Macmillan Publishers Limited All rights reserved
RMID: 0020122872
DOI: 10.1038/leu.2012.134
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.